

**Supplementary Table 1.**

Features	Exploration cohort				P-value	Total	
	Group 1		Group 2			N	%
	N	%	N	%			
<b>Total</b>	12	100.0	9	100.0		83	100.0
<b>Sex</b>							
Female	1	8.3	1	11.1	1.000 <sup>a</sup>	15	18.1
Male	11	91.7	8	88.9		68	81.9
<b>Age</b>							
<65	7	58.3	6	66.7	1.000 <sup>a</sup>	48	57.8
≥65	5	41.7	3	33.3		35	42.2
<b>Lauren classification</b>							
Intestinal type	8	66.6	6	66.7	0.425 <sup>a</sup>	58	69.9
Diffuse type	2	16.7	3	33.3		19	22.9
Mixed type	2	16.7	0	0.0		6	7.2
<b>Progression after starting HER2 treatment</b>							
Before 6 months	0	0.0	9	100.0	<0.001 <sup>a</sup>	24	28.9
After 6 months	2	16.7	0	0.0		34	41.0
Progression free at last follow-up	10	83.3	0	0.0		25	30.1
<b>Progression-free survival (months)</b>							
median [range]	22.5 [11.7-68.1]		4.3 [1.7-5.6]		<0.001 <sup>b</sup>	12.4 [5.3-23.3]	

<sup>a</sup>Fisher's exact test; <sup>b</sup>Mann-Whitney test